Meningitis due to Lyme disease
ICD-10 A69.21 is a billable code used to indicate a diagnosis of meningitis due to lyme disease.
Meningitis due to Lyme disease is a rare but serious complication of Lyme borreliosis, an infectious disease caused by the spirochete Borrelia burgdorferi, which is transmitted to humans through the bite of infected Ixodes ticks. The condition is characterized by inflammation of the protective membranes covering the brain and spinal cord, leading to symptoms such as severe headache, fever, neck stiffness, and altered mental status. Lyme meningitis typically occurs in the later stages of Lyme disease, often presenting weeks to months after the initial tick bite. Diagnosis is confirmed through clinical evaluation, serological testing for antibodies against Borrelia, and sometimes lumbar puncture to analyze cerebrospinal fluid (CSF). Geographic distribution of Lyme disease is primarily in the northeastern, north-central, and Pacific coastal regions of the United States, with endemic areas also found in parts of Europe and Asia. Awareness of Lyme meningitis is crucial for timely diagnosis and treatment, as early intervention with appropriate antibiotics can lead to favorable outcomes.
Detailed clinical history, laboratory results, and treatment plans.
Patients presenting with neurological symptoms after a known tick exposure.
Ensure that all relevant diagnostic tests are documented to support the diagnosis.
Neurological examination findings, imaging studies, and CSF analysis.
Patients with acute onset of meningitis symptoms and a history of Lyme disease.
Document any differential diagnoses considered and ruled out.
Used to confirm Lyme disease in patients presenting with meningitis symptoms.
Document the reason for testing and the patient's clinical presentation.
Infectious disease specialists should ensure comprehensive testing for Lyme disease.
Symptoms include severe headache, fever, neck stiffness, and altered mental status, often occurring weeks after a tick bite.
Diagnosis is made through clinical evaluation, serological testing for Borrelia antibodies, and analysis of cerebrospinal fluid.
